Clinica Baviera (CBAV) AI Stock Analysis

• Market Cap: €847.78M
• Dividend Yield: 3.31%
• Average Volume (3M): 2.20K
• Price to Earnings (P/E): 20.5
• Beta (1Y): 0.49
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,706
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.34
• Shares Outstanding: 16,307,580
• 10 Day Avg. Volume: 2,444
• 30 Day Avg. Volume: 2,202
• PEG Ratio: 1.07
• Price to Book (P/B): 5.24
• Price to Sales (P/S): 1.93
• P/FCF Ratio: 14.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: €60.00 ▲(26.85% Upside)

Clinica Baviera's strong financial performance and positive technical indicators are the primary drivers of its stock score. The company's robust profitability, efficient operations, and solid balance sheet position it well in the industry. The fair valuation and attractive dividend yield further support the stock's appeal.

Positive Factors

High profit margins

Very high gross margins and healthy net margins indicate strong pricing power and efficient clinical operations. Durable margins provide internal funding for equipment upgrades, training, and marketing, supporting sustained competitiveness and profitability across economic cycles.

Low leverage and strong ROE

Extremely low leverage combined with a high ROE signals efficient capital use and financial resilience. This balance sheet strength enables opportunistic investment, M&A or cyclical cushioning without materially increasing financial risk, supporting long-term strategic flexibility.

Consistent cash generation

Sustained free cash flow growth and OCF exceeding net income show reliable cash conversion. Durable cash generation funds capex for advanced medical tech, funds working capital, supports dividends and selective expansion, reducing reliance on external financing over time.

Negative Factors

Mature/slowing revenue growth

Evidence of decelerating top-line growth suggests the business is entering a mature phase, limiting organic upside. Over the medium term this pressures expectations for earnings expansion and forces focus on share gains, service diversification or M&A to sustain growth rates.

Declining equity ratio trend

A falling equity ratio, if persistent, erodes the capital cushion and may imply rising payout, buybacks, or asset reallocation. Over months this can reduce financial flexibility for capex or acquisitions, and increase sensitivity to revenue or margin shocks.

Limited recent investor disclosures/events

Absence of earnings call details and notable corporate events reduces forward-looking transparency. Over time this limits investor visibility into strategy execution, guidance and governance signals, potentially making it harder to assess management priorities and monitor long-term performance.

Clinica Baviera Business Overview & Revenue Model

Company Description

Clinica Baviera (CBAV) is a leading provider of ophthalmological services in Spain and several other countries, specializing in vision correction procedures such as LASIK and cataract surgery. The clinic operates a network of medical centers equipped with advanced technology and staffed by highly trained professionals to deliver quality eye care. In addition to surgical interventions, Clinica Baviera offers comprehensive eye examinations, diagnostic services, and post-operative care, focusing on improving patients' quality of life through enhanced vision.

How the Company Makes Money

Clinica Baviera generates revenue primarily through its core services, including laser eye surgeries, cataract surgeries, and other ophthalmological treatments. The company charges patients for these procedures, which often involve significant fees due to the advanced technology and expertise required. Additional revenue streams include consultations, eye examinations, and the sale of vision correction products such as contact lenses and glasses. CBAV has established partnerships with insurance companies, allowing patients to access services through their health plans, which can increase patient volume and overall revenue. Moreover, the company invests in marketing strategies to attract new clients and enhance brand visibility, contributing to its financial performance.

Clinica Baviera Financial Statement Overview

Summary

Clinica Baviera demonstrates strong financial performance with consistent revenue growth, robust profit margins, and efficient operations. The company maintains a solid balance sheet with low leverage and impressive returns on equity. Cash flow is strong, supporting growth and investment strategies.

Income Statement

Clinica Baviera demonstrates strong financial performance with consistent revenue growth and robust profit margins. The TTM data shows a Gross Profit Margin of 80.38% and a Net Profit Margin of 13.85%, indicating efficient cost management and profitability. The EBIT and EBITDA margins are healthy at 20.23% and 28.15%, respectively, reflecting strong operational efficiency. Revenue growth is steady, although slightly lower than previous years, suggesting a mature growth phase.

Balance Sheet

The balance sheet reflects a solid financial position with a low Debt-to-Equity Ratio of 0.10 in the TTM period, indicating low leverage and financial stability. The Return on Equity is impressive at 41.50%, showcasing effective use of equity to generate profits. The Equity Ratio stands at 42.29%, suggesting a balanced capital structure. However, the decrease in equity ratio over time could be a point of concern if it continues.

Cash Flow

Clinica Baviera's cash flow is strong, with a Free Cash Flow Growth Rate of 10.79% in the TTM period, indicating effective cash management and growth potential. The Operating Cash Flow to Net Income Ratio is 1.10, showing that operating cash flows are well-aligned with net income. The Free Cash Flow to Net Income Ratio of 0.63 suggests a healthy conversion of net income into free cash flow, supporting ongoing investments and debt servicing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	293.69M	262.65M	224.92M	198.45M	172.73M	122.63M
Gross Profit	181.00M	232.08M	197.85M	172.95M	151.25M	107.37M
EBITDA	84.56M	78.11M	67.22M	56.15M	53.49M	34.27M
Net Income	40.48M	40.20M	35.97M	29.52M	27.39M	13.94M
Balance Sheet
Total Assets	228.01M	211.95M	178.64M	150.10M	133.81M	120.92M
Cash, Cash Equivalents and Short-Term Investments	43.85M	38.58M	51.24M	38.99M	32.27M	26.94M
Total Debt	66.61M	63.47M	47.41M	47.81M	51.56M	54.84M
Total Liabilities	130.65M	113.59M	86.37M	81.74M	78.42M	76.02M
Stockholders Equity	96.44M	96.92M	91.00M	67.34M	54.60M	44.49M
Cash Flow
Free Cash Flow	46.65M	36.25M	35.13M	39.35M	36.28M	23.64M
Operating Cash Flow	72.21M	62.76M	57.81M	53.38M	46.86M	31.46M
Investing Cash Flow	-10.87M	-20.90M	-44.31M	-12.56M	-17.08M	-21.40M
Financing Cash Flow	-36.15M	-39.91M	-24.37M	-31.45M	-30.80M	-3.15M

Clinica Baviera Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 47.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Positive. The current price of 47.3 is below the 20-day moving average (MA) of 50.45, above the 50-day MA of 47.19, and above the 200-day MA of 42.67, indicating a bullish trend. The MACD of 1.29 indicates Negative momentum. The RSI at 68.28 is Neutral, neither overbought nor oversold. The STOCH value of 76.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:CBAV.

Clinica Baviera Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	78 Outperform	€1.59B	15.16	14.89%	3.51%	11.04%	8.29%
CBAV	76 Outperform	€847.78M	20.48	45.95%	3.31%	―	―
NTH	73 Outperform	€160.66M	14.60	38.28%	11.15%	-4.18%	4.98%
PRM	73 Outperform	€216.95M	15.37	―	3.37%	―	―
RJF	65 Neutral	€220.51M	50.28	2.03%	1.91%	-1.19%	-54.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATRY	42 Neutral	€228.70M	-9.29	-9.43%	―	15.90%	37.03%